Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ariflo (SmithKline Beecham plc).

W Brown1

  • 1PO Box 8139, Somerville, NJ 08876-8139, USA. BrownWM@aol.com

Idrugs : the Investigational Drugs Journal
|August 27, 2005
PubMed
Summary
This summary is machine-generated.

Ariflo, a phosphodiesterase (PDE)4 inhibitor, is undergoing clinical trials for chronic obstructive pulmonary disease (COPD) and asthma. Financial forecasts predict significant market potential for this promising respiratory medication.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring touch-colour associations in achromatopsia: A case study.

Cortex; a journal devoted to the study of the nervous system and behavior·2025
Same author

Advancing next-generation sequencing access: aspirations for next-generation sequencing policy and patient access in Hong Kong.

Hong Kong medical journal = Xianggang yi xue za zhi·2025
Same author

Effects of administration of mycobacterium cell wall fraction during the periovulatory period on embryo development following superovulation in virgin dairy heifers.

JDS communications·2024
Same author

Effects of mycobacterium cell wall fraction on embryo development following in vitro embryo production and pregnancy rates following embryo transfer in virgin dairy heifers.

Theriogenology·2023
Same author

Design and testing of the safety of the SARUS-CPR hood for novice resuscitators.

Scottish medical journal·2022
Same author

Diagnostic accuracy of an automated artificial intelligence derived right ventricular to left ventricular diameter ratio tool on CT pulmonary angiography to predict pulmonary hypertension at right heart catheterisation.

Clinical radiology·2022
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Drug Development

Background:

  • Ariflo (SB-207499) is an investigational phosphodiesterase (PDE)4 inhibitor.
  • SmithKline Beecham is developing Ariflo for respiratory conditions.
  • PDE4 inhibition is a therapeutic target for inflammatory airway diseases.

Purpose of the Study:

  • To evaluate the efficacy and safety of Ariflo in treating chronic obstructive pulmonary disease (COPD).
  • To assess Ariflo's potential as a treatment for asthma.
  • To track the progress of Ariflo through clinical development phases.

Main Methods:

  • Phase III clinical trials for chronic obstructive pulmonary disease (COPD).
  • Phase II clinical trials for asthma.
  • Ongoing clinical trials in Japan for bronchial asthma.

Related Experiment Videos

Main Results:

  • Ariflo is currently in active clinical development for COPD and asthma.
  • Phase II trials for bronchial asthma have commenced in Japan.
  • Financial analysts have projected substantial sales forecasts for Ariflo.

Conclusions:

  • Ariflo shows potential as a novel therapeutic agent for COPD and asthma.
  • The drug's progression through clinical trials indicates promising development.
  • Market predictions suggest significant commercial viability for Ariflo.